Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07610343

Intranasal Dexmedetomidine-Esketamine for Sleep and Cognition in Older Adults With Mild-to-Moderate Cognitive Impairment

Sponsor: Peking University First Hospital

View on ClinicalTrials.gov

Summary

Sleep is crucial for maintaining brain function and clearing metabolic waste products (such as proteins associated with Alzheimer's disease) from the brain . Continuous sleep disturbances may hinder this clearance process, thereby worsening cognitive impairment. This study aims to preliminarily explore whether a nasal spray combining dexmedetomidine and esketamine can safely and effectively improve sleep quality and cognitive function in older adults with mild-to-moderate cognitive impairment and comorbid sleep disorders. The study plans to enroll 60 older adults (aged 60 and older) who experience both sleep disorders and mild-to-moderate cognitive impairment. Participants will be randomly assigned to one of two groups: half will receive the dexmedetomidine-esketamine combination nasal spray, and the other half will receive an equal volume of saline nasal spray (as a placebo). Both groups will receive the nasal spray twice a week for 4 consecutive weeks (8 treatments in total). During each treatment session, a professional medical team will closely monitor participants' electrocardiogram (ECG), blood pressure, blood oxygen levels, and consciousness to ensure their safety. Additionally, participants will wear an actigraphy on the night of each treatment to objectively record their sleep patterns. Researchers will also conduct face-to-face follow-up visits at 1, 2, and 3 months after the treatment period ends to comprehensively evaluate improvements in sleep quality, cognitive function, mood, and activities of daily living. We hope this study will provide new treatment insights and options for improving the sleep and cognitive health of these patients.

Official title: Impact of Intranasal Dexmedetomidine-esketamine on Sleep Quality and Cognitive Function in Older Adults With Mild-to-moderate Cognitive Impairment: a Randomized, Double-blind, and Placebo-controlled Trial

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-06-01

Completion Date

2027-12

Last Updated

2026-05-27

Healthy Volunteers

Conditions

Sleep Disorder (Disorder)Cognitive Impairment

Interventions

DRUG

Dexmedetomidine-esketamine combination

The experimental intervention is a combination of dexmedetomidine (approximately 0.4 μg/kg) and esketamine (approximately 0.2 mg/kg). The mixture is prepared using dexmedetomidine nasal spray and esketamine injection with normal saline. It is administered via a customized nasal spray device. The administration alternates between both nostrils every 5 minutes until the target dose is reached. Participants receive this intervention twice a week for 4 consecutive weeks, totaling 8 sessions

DRUG

Placebo

The placebo intervention consists of an equal volume of 0.9% normal saline. It is prepared in the identical customized nasal spray device to match the appearance of the experimental drug. It is administered using the exact same alternating nostril procedure, volume, and frequency (twice a week for 4 consecutive weeks, totaling 8 sessions) as the intervention group.

Inclusion Criteria: 1. Age ≥ 60 years. 2. Meeting the clinical diagnostic criteria for Alzheimer's disease, with mild cognitive impairment (MoCA score 18-25) or moderate cognitive impairment (MoCA score 10-17) due to Alzheimer's disease. 3. Comorbid sleep disorder (Pittsburgh Sleep Quality Index \[PSQI\] score ≥ 7). 4. Signed informed consent Exclusion Criteria: 1. Cognitive impairment/dementia due to other causes (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease dementia). 2. Unsuitable for intranasal administration due to nasal diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause). 3. Inability to communicate due to visual, auditory, speech, or other reasons, or Mini-Mental State Examination (MMSE) score ≤ 9 or MoCA score ≤ 9. 4. History of schizophrenia, epilepsy, Parkinson's disease, or confirmed diagnosis of glaucoma, hyperthyroidism, pheochromocytoma, or myasthenia gravis. 5. Confirmed diagnosis of restless legs syndrome, sleep apnea, or high risk for moderate-to-severe sleep apnea based on STOP-Bang assessment, or Body Mass Index (BMI) \> 30 kg/m2. 6. History of stroke or transient ischemic attack within 12 months prior to enrollment, confirmed intracranial aneurysm, or elevated intracranial pressure from any cause. 7. Uncontrolled hypertension (e.g., hypertensive crisis or systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg prior to enrollment), myocardial infarction, unstable angina, revascularization surgery within 12 months prior to enrollment, or NYHA class III. 8. Sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), atrioventricular block above degree II without a pacemaker, corrected QT interval (Fridericia-corrected QTcF) ≥ 450 ms, or other severe arrhythmias (e.g., frequent premature ventricular contractions). 9. Uncontrolled diabetes (e.g., HbA1c \> 9%, diabetic ketosis, hyperglycemic coma, or hypoglycemia). 10. Severe hepatic dysfunction (Child-Pugh Class C), renal dysfunction (eGFR ≤ 30 ml/min/1.73m2), respiratory insufficiency (SpO2 \< 93% on room air), or other severe diseases (e.g., frailty preventing independent walking, advanced-stage tumors). 11. Alcohol or drug dependence (manifested as strong craving, uncontrolled use, and withdrawal symptoms upon cessation), or use of contraindicated medications. 12. Major surgery under general anesthesia within 12 weeks prior to enrollment, or planned surgery within 12 weeks. 13. Allergy to dexmedetomidine and/or esketamine. 14. Participation in other interventional clinical studies. 15. Any other conditions deemed unsuitable for study inclusion by the investigator.

Locations (1)

Peking University First Hospital

Beijing, China